王杭祥课题组

summary
学习经历：
2002年本科毕业于浙江大学材料与化学工程学院，期间被选派至日本福井大学材料开发工学部交换留学1年。
2006年获大阪大学(日本)工学研究科分子化学专业硕士学位。
2010年毕业于京都大学(日本)工学研究科合成生物化学专业，获工学博士学位。
工作经历：
浙江大学医学院博士后(2011.3-2014.1)
助理研究员(2011.6-2014.12)
副研究员(2015.1-2019.12)
研究员(2020.1-)
现为浙江大学医学院附属第一医院卫生部多器官联合移植研究重点实验室PI，博士生导师。
谷歌学术个人主页：https:\/\/scholar.google.com\/citations?user=8NI3ykwAAAAJ&hl=en&oi=ao
MyORCID:http:\/\/orcid.org\/0000-0001-6370-9728
实验室长期招聘博士后研究人员，待遇从优。有兴趣的同学请跟我联系。
Selected Publications:
1) Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies, Y. Wang, H. Xie, B. Xie, X. Chen, B. Yang, J. Jin, J. Wan, T. Li, W. Han, S. Fang, andH. Wang*, Biomaterials, 2021, 270, 120705(IF:10.317).
2) Quantitative Self-Assembly of Photoactivatable Small Molecular Prodrug Cocktails for Safe and Potent Cancer Chemo-Photodynamic Therapy, L. Huang, J. Wan, H. Wu, X. Chen, Q. Bian, L. Shi, X. Jiang, A. Yuan, J. Gao*, andH. Wang*, Nano Today, 2021, 36, 101030 (IF: 16.907).
3) Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy, X. Chen, Z. Hu, L. Zhou, F. Zhang, J. Wan, and H. Wang*, Nanoscale Horizons, 2021, 6, 33-42 (IF: 9.927).
4) Quantum dots-based hydrogels for sensing applications, J. Zhang, J. Jin, J. Wan, S. Jiang, W. Wang, X. Gong*, and H. Wang*, Chemical Engineering Journal, 2021, 408, 127351 (IF: 10.652).
5) Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer, J. Wan, L. Huang, J. Cheng, F. Huang, J. Jin, and H. Wang*, Theranostics, 2021, in press (IF: 8.579).
6) Target-Oriented Delivery of Self-Assembled Immunosuppressant Cocktails Prolongs Allogeneic Orthotopic Liver Transplant Survival, H. Xie,^#H. Zhu,^#K. Zhou, J. Wan, L. Zhang, Z. Yang, L. Zhou, X. Chen, X. Xu, S. Zheng,* andH. Wang*,J. Controlled Release,2020, 328, 237-250 (IF: 7.727).
7) Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts,L. Shi, Y. Wang, Q. Wang, Z. Jiang, L. Ren, Y. Yan, Z. Liu, J. Wan, L. Huang, B. Cen, W. Han*, andH. Wang*,J. Controlled Release,2020, 324, 289-302 (IF: 7.727).
8) Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo\/photodynamic efficacy of patient-derived melanoma, L. Huang, X. Chen, Q. Bian, F. Zhang, H. Wu,H. Wang*, and J. Gao*,J. Controlled Release,2020, 328, 325-338 (IF: 7.727).
9) Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy,J. Wan, Y. Qiao, X. Chen, J. Wu, L. Zhou, J. Zhang, S. Fang andH. Wang*,Adv. Funct. Mater.,2018, 28, ** (IF: 16.836).
10) New Generation Nanomedicines Constructed from Self-Assembling Small Molecule Prodrugs Alleviate Cancer Drug Toxicity,H. Wang*, Z. Lu, L. Wang, T. Guo, J. Wu, Z. Li, D. Jiang, P. Song, H. Xie, L. Zhou, X. Xu and S. Zheng*,Cancer Res.,2017, 77, 6963-6974 (IF: 9.727).
11) Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy,H. Wang, H. Xie, J. Wang, J. Wu, X. Ma, L. Li, X. Wei, Q. Ling, P. Song, L. Zhou, X. Xu,* and S. Zheng*,Adv. Funct. Mater.,2015, 25, 4956-4965 (IF: 16.836).
12) Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery Platforms for enhanced antitumor efficacy,H. Wang, H. Xie, J. Wu, X. Wei, L. Zhou, X. Xu,* and S. Zheng*,Angew. Chem. Int. Ed.,2014, 53, 11532-11537 (IF: 12.959).
13) Chemical cell-surface receptor engineering using affinity-guided, multivalent organocatalysts,H. Wang, Y. Koshi, D. Minato, H. Nonaka, S Kiyonaka, Y. Mori, S. Tsukiji and I. Hamachi*,J. Am. Chem. Soc.,2011, 133, 12220-12228 (IF: 14.612).
14) Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection,R. Lei, J. Hou, Q. Chen, W. Yuan, B. Cheng, Y. Sun, Y. Jin, L. Ge, S. A. Ben-Sasson,H. Wang*, W. Lu*, X. Fang*,ACS Nano,2018, 12, 5284-5296 (IF: 14.588).
15) ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination Repair,G. Chen*, J. Chen, Y. Qiao, Y. Shi, W. Liu, Q. Zeng, X. Shi, Y. Sun, X. Liu, T. Li, L. Zhou, J. Wan,H. Wang*and F. Wang*,Nucleic Acids Res.,2018, 46, 1266-1279 (IF: 11.501).
16)Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer,W. Han*, B. Xie, Y. Li, L. Shi, J. Wan, X. Chen andH. Wang*,Theranostics,2019, 9, 7458-7473 (IF: 8.579).
17) Polyactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma,H. Wang*, L. Zhou, K. Xie, J. Wu, P. Song, H. Xie, L. Zhou, J. Liu, X. Xu, Y. Shen and S. Zheng*,Theranostics,2018, 8, 3949-3963 (IF: 8.579).
18) Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations,H. Wang*, J. Chen, C. Xu, M. Tayier, J. Zhou, J. Zhang, J. Wu, Z. Ye, T. Fang, W. Han*,Theranostics,2017, 7, 3638-3652 (IF: 8.579).
19) Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma,L. Wu, F. Zhang, X. Chen, J. Wan, Y. Wang, T. Li, andH. Wang*,ACS Applied Materials & Interfaces,2020, 12, 3327-3340 (IF: 8.758).
20) Dimerization-Induced Self-Assembly of a Redox-Responsive Prodrug into Nanoparticles for Improved Therapeutic Index, L. Zhou, H. Xie, X. Chen, J. Wan, S. Xu, Y. Han, D. Chen, Y. Qiao, L. Zhou, S. Zheng*, andH. Wang*,Acta Biomaterialia,2020, 113, 464-477 (IF: 7.242).
21)Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies,B. Xie, J. Wan, X. Chen, W. Han* andH. Wang*,Mol. Cancer Ther.,2020, 19, 822-834 (IF: 5.615).

template_id
17
photo
\/attachments\/73\/-**.jpg
research_field
目前的研究方向集中在：\r\r1，用于体内核酸药物(siRNA, miRNA等)输送新方法及新材料的开发。\r2，抗肿瘤创新药物及纳米制剂的研发。\r3，用于肝癌化疗药物及分子靶向药物的研发。\r4，新型贵金属抗癌药物研发及分子机制研究。\r5，肿瘤耐药分子机制及靶向治疗研究\r\r\r\r
status
1
opendate
2014-08-07 21:57:20
access_type
access_count
43202
score
connect

selfintroduction
2002年本科毕业于浙江大学材料与化学工程学院，期间被选派至日本福井大学材料开发工学部交换留学1年。
2006年获大阪大学(日本)工学研究科分子化学专业硕士学位。
2010年毕业于京都大学(日本)工学研究科合成生物化学专业，并获工学博士学位。
现为浙江大学医学院附属第一医院卫生部多器官联合移植研究重点实验室PI，博士生导师。

url

telephone

email
wanghx@zju.edu.cn
address
浙江大学紫金港校区医学院科研楼C幢702
research
mypage_id
5537
work_title
learn_degree
work_post
research_orientation
handle
wanghx
main_status
1
access_uid_status
1
theme_id
qrcode_status
1
gmt_qrcode
2021-01-24 20:14:55
content
学习经历：
2002年本科毕业于浙江大学材料与化学工程学院，期间被选派至日本福井大学材料开发工学部交换留学1年。
2006年获大阪大学(日本)工学研究科分子化学专业硕士学位。
2010年毕业于京都大学(日本)工学研究科合成生物化学专业，获工学博士学位。
工作经历：
浙江大学医学院博士后(2011.3-2014.1)
助理研究员(2011.6-2014.12)
副研究员(2015.1-2019.12)
研究员(2020.1-)
现为浙江大学医学院附属第一医院卫生部多器官联合移植研究重点实验室PI，博士生导师。
谷歌学术个人主页：https:\/\/scholar.google.com\/citations?user=8NI3ykwAAAAJ&hl=en&oi=ao
MyORCID:http:\/\/orcid.org\/0000-0001-6370-9728
实验室长期招聘博士后研究人员，待遇从优。有兴趣的同学请跟我联系。
Selected Publications:
1) Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies, Y. Wang, H. Xie, B. Xie, X. Chen, B. Yang, J. Jin, J. Wan, T. Li, W. Han, S. Fang, andH. Wang*, Biomaterials, 2021, 270, 120705(IF:10.317).
2) Quantitative Self-Assembly of Photoactivatable Small Molecular Prodrug Cocktails for Safe and Potent Cancer Chemo-Photodynamic Therapy, L. Huang, J. Wan, H. Wu, X. Chen, Q. Bian, L. Shi, X. Jiang, A. Yuan, J. Gao*, andH. Wang*, Nano Today, 2021, 36, 101030 (IF: 16.907).
3) Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy, X. Chen, Z. Hu, L. Zhou, F. Zhang, J. Wan, and H. Wang*, Nanoscale Horizons, 2021, 6, 33-42 (IF: 9.927).
4) Quantum dots-based hydrogels for sensing applications, J. Zhang, J. Jin, J. Wan, S. Jiang, W. Wang, X. Gong*, and H. Wang*, Chemical Engineering Journal, 2021, 408, 127351 (IF: 10.652).
5) Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer, J. Wan, L. Huang, J. Cheng, F. Huang, J. Jin, and H. Wang*, Theranostics, 2021, in press (IF: 8.579).
6) Target-Oriented Delivery of Self-Assembled Immunosuppressant Cocktails Prolongs Allogeneic Orthotopic Liver Transplant Survival, H. Xie,^#H. Zhu,^#K. Zhou, J. Wan, L. Zhang, Z. Yang, L. Zhou, X. Chen, X. Xu, S. Zheng,* andH. Wang*,J. Controlled Release,2020, 328, 237-250 (IF: 7.727).
7) Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts,L. Shi, Y. Wang, Q. Wang, Z. Jiang, L. Ren, Y. Yan, Z. Liu, J. Wan, L. Huang, B. Cen, W. Han*, andH. Wang*,J. Controlled Release,2020, 324, 289-302 (IF: 7.727).
8) Photosensitizer-stabilized self-assembling nanoparticles potentiate chemo\/photodynamic efficacy of patient-derived melanoma, L. Huang, X. Chen, Q. Bian, F. Zhang, H. Wu,H. Wang*, and J. Gao*,J. Controlled Release,2020, 328, 325-338 (IF: 7.727).
9) Structure-Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy,J. Wan, Y. Qiao, X. Chen, J. Wu, L. Zhou, J. Zhang, S. Fang andH. Wang*,Adv. Funct. Mater.,2018, 28, ** (IF: 16.836).
10) New Generation Nanomedicines Constructed from Self-Assembling Small Molecule Prodrugs Alleviate Cancer Drug Toxicity,H. Wang*, Z. Lu, L. Wang, T. Guo, J. Wu, Z. Li, D. Jiang, P. Song, H. Xie, L. Zhou, X. Xu and S. Zheng*,Cancer Res.,2017, 77, 6963-6974 (IF: 9.727).
11) Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy,H. Wang, H. Xie, J. Wang, J. Wu, X. Ma, L. Li, X. Wei, Q. Ling, P. Song, L. Zhou, X. Xu,* and S. Zheng*,Adv. Funct. Mater.,2015, 25, 4956-4965 (IF: 16.836).
12) Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery Platforms for enhanced antitumor efficacy,H. Wang, H. Xie, J. Wu, X. Wei, L. Zhou, X. Xu,* and S. Zheng*,Angew. Chem. Int. Ed.,2014, 53, 11532-11537 (IF: 12.959).
13) Chemical cell-surface receptor engineering using affinity-guided, multivalent organocatalysts,H. Wang, Y. Koshi, D. Minato, H. Nonaka, S Kiyonaka, Y. Mori, S. Tsukiji and I. Hamachi*,J. Am. Chem. Soc.,2011, 133, 12220-12228 (IF: 14.612).
14) Self-assembling myristoylated human alpha-defensin 5 as a next-generation nanobiotics potentiates therapeutic efficacy in bacterial infection,R. Lei, J. Hou, Q. Chen, W. Yuan, B. Cheng, Y. Sun, Y. Jin, L. Ge, S. A. Ben-Sasson,H. Wang*, W. Lu*, X. Fang*,ACS Nano,2018, 12, 5284-5296 (IF: 14.588).
15) ZNF830 Mediates Cancer Chemoresistance through Promoting Homologous-Recombination Repair,G. Chen*, J. Chen, Y. Qiao, Y. Shi, W. Liu, Q. Zeng, X. Shi, Y. Sun, X. Liu, T. Li, L. Zhou, J. Wan,H. Wang*and F. Wang*,Nucleic Acids Res.,2018, 46, 1266-1279 (IF: 11.501).
16)Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer,W. Han*, B. Xie, Y. Li, L. Shi, J. Wan, X. Chen andH. Wang*,Theranostics,2019, 9, 7458-7473 (IF: 8.579).
17) Polyactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma,H. Wang*, L. Zhou, K. Xie, J. Wu, P. Song, H. Xie, L. Zhou, J. Liu, X. Xu, Y. Shen and S. Zheng*,Theranostics,2018, 8, 3949-3963 (IF: 8.579).
18) Cancer Nanomedicines Stabilized by π-π Stacking between Heterodimeric Prodrugs Enable Exceptionally High Drug Loading Capacity and Safer Delivery of Drug Combinations,H. Wang*, J. Chen, C. Xu, M. Tayier, J. Zhou, J. Zhang, J. Wu, Z. Ye, T. Fang, W. Han*,Theranostics,2017, 7, 3638-3652 (IF: 8.579).
19) Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma,L. Wu, F. Zhang, X. Chen, J. Wan, Y. Wang, T. Li, andH. Wang*,ACS Applied Materials & Interfaces,2020, 12, 3327-3340 (IF: 8.758).
20) Dimerization-Induced Self-Assembly of a Redox-Responsive Prodrug into Nanoparticles for Improved Therapeutic Index, L. Zhou, H. Xie, X. Chen, J. Wan, S. Xu, Y. Han, D. Chen, Y. Qiao, L. Zhou, S. Zheng*, andH. Wang*,Acta Biomaterialia,2020, 113, 464-477 (IF: 7.242).
21)Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies,B. Xie, J. Wan, X. Chen, W. Han* andH. Wang*,Mol. Cancer Ther.,2020, 19, 822-834 (IF: 5.615).

column_name
个人简介